Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Vertex Pharmaceuticals ( VRTX) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.5%. By the end of trading, Vertex Pharmaceuticals rose $1.44 (3.4%) to $43.25 on light volume. Throughout the day, 1.7 million shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2.4 million shares. The stock ranged in a price between $41.92-$43.37 after having opened the day at $41.92 as compared to the previous trading day's close of $41.81. Other companies within the Drugs industry that increased today were: Opexa Therapeutics ( OPXA), up 25%, Vanda Pharmaceuticals ( VNDA), up 18.6%, Aoxing Pharmaceutical Company ( AXN), up 14.8%, and MEI Pharma ( MEIP), up 14.6%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for the treatment of serious diseases worldwide. Vertex Pharmaceuticals has a market cap of $9.06 billion and is part of the health care sector. The company has a P/E ratio of 67.4, above the S&P 500 P/E ratio of 17.7. Shares are up 25.8% year to date as of the close of trading on Monday. Currently there are 13 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share.

On the negative front, Hemispherx Biopharma ( HEB), down 44.1%, Galena Biopharma ( GALE), down 17%, Idera Pharmaceuticals ( IDRA), down 11.5%, and Cardiome Pharma Corporation ( CRME), down 11.4%, were all laggards within the drugs industry with BioMarin Pharmaceuticals ( BMRN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

HOLIDAY SPECIAL: Let Jim Cramer show you every trade he is making in his $2.5 Million portfolio. Join now for 14-days FREE. Sign up today to get e-mail alerts before every trade.
null

If you liked this article you might like

Vertex Pharmaceuticals Could Be Headed Higher Once Again

Omeros Shares Lower After Completing Stock Offering, Juno Dips - Biotech Movers

10 High-Yielding Stocks to Own Ahead of a Surprising Late Summer Market Swoon

Vertex Pharmaceuticals: Looking East, West and to the Quants

Vertex Pharmaceuticals: Looking East, West and to the Quants